Search

Mitotane

It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma[A263010] and is used off-label for the management of Cushing's syndrome.[A263016] … Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.

Adrafinil

It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. … Adrafinil does not currently have FDA approval and is thus unregulated in the United States.

Mandelic acid

Mandelic acid is an approved aromatic, alpha hydroxy acid [L5458]. Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.

Emeramide

Emeramide has been used in trials studying the treatment of Mercury Poisoning.

Trinitrotoluene

Trinitrotoluene is an explosive chemical that can cause skin irritation and other toxic consequences.

Lonidamine

In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).

Vidarabine

It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the

p-Phenylenediamine

Almonertinib

[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.